Related Experiment Video
Updated: Aug 24, 2026

14:55
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
Published on: December 3, 2013
Human recombinant interferonalpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot
Lori A Thompson1, Terry L Grieshaber, Larry Glickman
1Animal Allergy and Skin Disease Center, 6327 North Keystone Avenue, Indianapolis, IN, 46220, USA.
Abstract:
The oral use of human recombinant interferonalpha-2b at 1,000 IU/ml/day appeared to provide only a transient benefit as compared with placebo for management of idiopathic recurrent superficial pyoderma in dogs. Further investigation using a larger population of dogs is needed to determine whether interferon is effective for long-term treatment of this condition.
